Frontiers in Immunology (Dec 2022)
Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections
- Mohamed Ibraheem Mahmoud Ahmed,
- Mohamed Ibraheem Mahmoud Ahmed,
- Paulina Diepers,
- Christian Janke,
- Michael Plank,
- Tabea M. Eser,
- Tabea M. Eser,
- Raquel Rubio-Acero,
- Anna Fuchs,
- Olga Baranov,
- Olga Baranov,
- Noemi Castelletti,
- Inge Kroidl,
- Inge Kroidl,
- Laura Olbrich,
- Laura Olbrich,
- Laura Olbrich,
- Bernadette Bauer,
- Danni Wang,
- Martina Prelog,
- Johannes G. Liese,
- Christina Reinkemeyer,
- Michael Hoelscher,
- Michael Hoelscher,
- Philipp Steininger,
- Klaus Überla,
- Andreas Wieser,
- Andreas Wieser,
- Christof Geldmacher,
- Christof Geldmacher
Affiliations
- Mohamed Ibraheem Mahmoud Ahmed
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Mohamed Ibraheem Mahmoud Ahmed
- German Centre for Infection Research (DZIF), Munich, Germany
- Paulina Diepers
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Christian Janke
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Michael Plank
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Tabea M. Eser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Tabea M. Eser
- German Centre for Infection Research (DZIF), Munich, Germany
- Raquel Rubio-Acero
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Anna Fuchs
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Olga Baranov
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Olga Baranov
- German Centre for Infection Research (DZIF), Munich, Germany
- Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Inge Kroidl
- German Centre for Infection Research (DZIF), Munich, Germany
- Laura Olbrich
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Laura Olbrich
- German Centre for Infection Research (DZIF), Munich, Germany
- Laura Olbrich
- Oxford Vaccine Group, Department of Paediatrics, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- Bernadette Bauer
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Danni Wang
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Martina Prelog
- Pediatric Rheumatology/Special Immunology, Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany
- Johannes G. Liese
- Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany
- Christina Reinkemeyer
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Michael Hoelscher
- German Centre for Infection Research (DZIF), Munich, Germany
- Philipp Steininger
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- Klaus Überla
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Andreas Wieser
- German Centre for Infection Research (DZIF), Munich, Germany
- Christof Geldmacher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Christof Geldmacher
- German Centre for Infection Research (DZIF), Munich, Germany
- DOI
- https://doi.org/10.3389/fimmu.2022.1026473
- Journal volume & issue
-
Vol. 13
Abstract
SARS-CoV-2 vaccine breakthrough infections frequently occurred even before the emergence of Omicron variants. Yet, relatively little is known about the impact of vaccination on SARS-CoV-2-specific T cell and antibody response dynamics upon breakthrough infection. We have therefore studied the dynamics of CD4 and CD8 T cells targeting the vaccine-encoded Spike and the non-encoded Nucleocapsid antigens during breakthrough infections (BTI, n=24) and in unvaccinated control infections (non-BTI, n=30). Subjects with vaccine breakthrough infection had significantly higher CD4 and CD8 T cell responses targeting the vaccine-encoded Spike during the first and third/fourth week after PCR diagnosis compared to non-vaccinated controls, respectively. In contrast, CD4 T cells targeting the non-vaccine encoded Nucleocapsid antigen were of significantly lower magnitude in BTI as compared to non-BTI. Hence, previous vaccination was linked to enhanced T cell responses targeting the vaccine-encoded Spike antigen, while responses against the non-vaccine encoded Nucleocapsid antigen were significantly attenuated.
Keywords